Results 191 to 200 of about 243,736 (290)
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
Exploratory Pain Profiling With Quantitative Sensory Testing (QST) in Episodic and Chronic Migraine. [PDF]
van Welie RF +5 more
europepmc +1 more source
[Sensation disorders in cervical pyramidal tractotomies].
A, TOLOSA +2 more
openaire +1 more source
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Factor analysis of defecation status in the general elderly population: the Yamagata Cohort Study. [PDF]
Kataoka H, Konta T, Sasaki Y, Ueno Y.
europepmc +1 more source
Burning Mouth Syndrome as a Central Pain Disorder: A Case Study Demonstrating Response to Occipital Nerve Block Treatment. [PDF]
Shemesh SZ, Kelmer P, Ungar L.
europepmc +1 more source
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart +14 more
wiley +1 more source
Childhood-Onset Huntington's Disease-Like Presentation of SCA17 with Intermediate Repeats, A Case Report. [PDF]
Berns M, Jensen K, Speltz L, Almeida LB.
europepmc +1 more source

